518 related articles for article (PubMed ID: 34174700)
1. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
[TBL] [Abstract][Full Text] [Related]
2. Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
Griffante G; Chandel S; Ferrante D; Caneparo V; Capello D; Bettio V; Borgogna C; Aleni C; Esposito S; Sarro A; Vasile A; Comba M; Testa T; Cotrupi G; De Andrea M; Bortoluzzi S; Gariglio M
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835076
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population.
Bichara CDA; da Silva Graça Amoras E; Vaz GL; da Silva Torres MK; Queiroz MAF; do Amaral IPC; Vallinoto IMVC; Bichara CNC; Vallinoto ACR
BMC Infect Dis; 2021 May; 21(1):443. PubMed ID: 33992073
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
Higgins RL; Rawlings SA; Case J; Lee FY; Chan CW; Barrick B; Burger ZC; Yeo KJ; Marrinucci D
PLoS One; 2021; 16(3):e0247797. PubMed ID: 33661960
[TBL] [Abstract][Full Text] [Related]
6. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
[TBL] [Abstract][Full Text] [Related]
7. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
8. IgA dominates the early neutralizing antibody response to SARS-CoV-2.
Sterlin D; Mathian A; Miyara M; Mohr A; Anna F; Claër L; Quentric P; Fadlallah J; Devilliers H; Ghillani P; Gunn C; Hockett R; Mudumba S; Guihot A; Luyt CE; Mayaux J; Beurton A; Fourati S; Bruel T; Schwartz O; Lacorte JM; Yssel H; Parizot C; Dorgham K; Charneau P; Amoura Z; Gorochov G
Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33288662
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
Glück V; Grobecker S; Tydykov L; Salzberger B; Glück T; Weidlich T; Bertok M; Gottwald C; Wenzel JJ; Gessner A; Schmidt B; Peterhoff D
Infection; 2021 Aug; 49(4):739-746. PubMed ID: 33689159
[TBL] [Abstract][Full Text] [Related]
10. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
[TBL] [Abstract][Full Text] [Related]
11. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
12. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection.
Dehgani-Mobaraki P; Zaidi AK; Yadav N; Floridi A; Floridi E
Clin Immunol; 2021 Sep; 230():108814. PubMed ID: 34343708
[TBL] [Abstract][Full Text] [Related]
14. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
15. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
Maine GN; Lao KM; Krishnan SM; Afolayan-Oloye O; Fatemi S; Kumar S; VanHorn L; Hurand A; Sykes E; Sun Q
J Clin Virol; 2020 Dec; 133():104663. PubMed ID: 33161369
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19.
Yan X; Chen G; Jin Z; Zhang Z; Zhang B; He J; Yin S; Huang J; Fan M; Li Z; Chen F; Zeng Y; Han X; Zhu Y
J Med Virol; 2022 Jan; 94(1):380-383. PubMed ID: 34403142
[TBL] [Abstract][Full Text] [Related]
19. IgG Antibodies, SARS-CoV-2 Load, and Prognostic Indicators in Patients with Severe and Mild COVID-19 in Japan.
Kashiwagi K; Maeda T; Yoshizawa S; Sato T; Aoki K; Ishii Y; Tateda K
J Nippon Med Sch; 2021 Sep; 88(4):380-383. PubMed ID: 33250476
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
